Biotech

All Articles

AN 2 halves headcount, stops period 3 trial after data dissatisfy

.AN2 Rehabs is reviewing its own organization in action to poor midphase data, promising to lay off ...

Merck pays out $700M for bispecific, spying autoimmune position and also possibility to challenge Amgen in cancer

.Merck &amp Co. is paying out $700 thousand beforehand to challenge Amgen in a blood stream cancer c...

Gilead spends J&ampJ $320M to leave licensing package for seladelpar

.With Gilead Sciences about to an FDA selection for its own liver illness medication seladelpar, the...

' All hands on deck' at Lilly as peers target weight problems market

.CEO David Ricks can observe the companies establishing outdoors tents at basecamp responsible for E...

Entero laying off team, leaving workplace and stopping briefly R&ampD

.Bed mattress Liquidators has actually transformed Entero Rehabs white as a piece. The collector pur...

Exelixis goes down ADC after deciding it is actually no suit for Tivdak

.Exelixis is actually surrendering on its own tissue factor (TF)- targeting antibody-drug conjugate ...

Relay loses interest in SHP2 prevention after Genentech leaves

.3 full weeks after Roche's Genentech system walked away from an SHP2 inhibitor contract, Relay Reha...

Stoke's Dravet disorder med launched of predisposed medical grip

.Stoke Therapies' Dravet syndrome drug has actually been actually without a predisposed grip, gettin...

Fierce Biotech's Gabrielle Masson offers Strong 15 at NYSE

.Tough Biotech Partner Editor Gabrielle Masson offered the 2024 training class of Tough 15 champions...

Novo Nordisk centers once-monthly GLP-1\/ GIP agonist, MASH possibility

.Novo Nordisk has axed its once-monthly dual GLP-1/ GIP receptor agonist, finishing (PDF) growth of ...